×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ITCI – intra-cellular therapies inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ITCI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/8
01:36 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
1/31
07:31 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was downgraded by analysts at Canaccord Genuity Group Inc. from a "buy" rating to a "hold" rating. They now have a $132.00 price target on the stock, up previously from $119.00.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) was downgraded by analysts at Canaccord Genuity Group Inc. from a "buy" rating to a "hold" rating. They now have a $132.00 price target on the stock, up previously from $119.00.
1/30
02:27 pm
itci
Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain [Yahoo! Finance]
Low
Report
Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain [Yahoo! Finance]
1/28
11:15 am
itci
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK and ITCI on Behalf of Shareholders
Low
Report
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK and ITCI on Behalf of Shareholders
1/23
02:08 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
1/22
12:21 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $132.00 price target on the stock, up previously from $108.00.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $132.00 price target on the stock, up previously from $108.00.
1/22
07:53 am
itci
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales [BNN Bloomberg (Canada)]
Low
Report
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales [BNN Bloomberg (Canada)]
1/16
12:10 pm
itci
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
07:30 am
itci
intra-cellular therapies inc.
MISS
Report
9.6%
intra-cellular therapies inc.
8/7/2024
07:30 am
itci
intra-cellular therapies inc.
BEAT
Report
-5.8%
intra-cellular therapies inc.
5/7/2024
07:30 am
itci
intra-cellular therapies inc.
BEAT
Report
-2.9%
intra-cellular therapies inc.
2/22/2024
07:30 am
itci
intra-cellular therapies inc.
BEAT
Report
-4.1%
intra-cellular therapies inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/7
10:24 am
itci
Form SCHEDULE 13G/A Intra-Cellular Therapies Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A Intra-Cellular Therapies Filed by: FMR LLC
2/5
05:23 pm
itci
Form PREM14A Intra-Cellular Therapies For: Feb 05
Low
Report
Form PREM14A Intra-Cellular Therapies For: Feb 05
2/4
05:32 pm
itci
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Mates Sharon
Low
Report
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Mates Sharon
2/4
05:31 pm
itci
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Neumann Mark
Low
Report
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Neumann Mark
2/4
05:31 pm
itci
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Halstead Michael
Low
Report
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Halstead Michael
2/4
05:29 pm
itci
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Durgam Suresh K.
Low
Report
Form 4 Intra-Cellular Therapies For: Jan 31 Filed by: Durgam Suresh K.
2/4
05:01 pm
itci
Form 4 Intra-Cellular Therapies For: Feb 03 Filed by: Narula Sanjeev
Low
Report
Form 4 Intra-Cellular Therapies For: Feb 03 Filed by: Narula Sanjeev
1/22
05:25 pm
itci
Form DFAN14A Intra-Cellular Therapies Filed by: JOHNSON & JOHNSON
Low
Report
Form DFAN14A Intra-Cellular Therapies Filed by: JOHNSON & JOHNSON
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/15
Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating.
5.8%
1/6 Form S-3ASR Intra-Cellular Therapies 6.9%
9/7 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.4%
4/29 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast 7.4%
8/5 Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA 8.5%
4/7 Intra-Cellular Therapies: This Small Cap Biotech Will Not Be Small For Long [Seeking Alpha] 11.4%
7/8 Intra-Cellular drug fails bipolar depression study; shares fall 14% [Reuters (UK)] 12.8%
6/14 Form DEFA14A Intra-Cellular Therapies 13.1%
6/13 Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults 14.3%
12/23 FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults 194.7%
1/6 Form S-3ASR Intra-Cellular Therapies 6.9%
9/7 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 7.4%
4/29 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast 7.4%
8/5 Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA 8.5%
4/7 Intra-Cellular Therapies: This Small Cap Biotech Will Not Be Small For Long [Seeking Alpha] 11.4%
7/8 Intra-Cellular drug fails bipolar depression study; shares fall 14% [Reuters (UK)] 12.8%
6/14 Form DEFA14A Intra-Cellular Therapies 13.1%
6/13 Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults 14.3%
12/23 FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults 194.7%
TOP News Decliners
1/8
Form 4 Intra-Cellular Therapies For: Jan 06 Filed by: Hineline Lawrence J.
-5.1%
2/21 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.9%
9/12 Form 424B3 Intra-Cellular Therapies -7.6%
7/24 Form 8-K Intra-Cellular Therapies For: Jul 23 -8.2%
6/19 Form 4/A Intra-Cellular Therapies For: Nov 22 Filed by: Alafi Christopher D -8.4%
3/18 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.7%
1/7 Intra-Cellular Therapies Prices Public Offering of Common Stock -12.7%
3/6 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -13.4%
12/23 Intra-Cellular drug approval augurs well for CNS stocks, Stifel says [Seeking Alpha] -14.1%
7/8 Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression -16.4%
2/21 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) -6.9%
9/12 Form 424B3 Intra-Cellular Therapies -7.6%
7/24 Form 8-K Intra-Cellular Therapies For: Jul 23 -8.2%
6/19 Form 4/A Intra-Cellular Therapies For: Nov 22 Filed by: Alafi Christopher D -8.4%
3/18 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -8.7%
1/7 Intra-Cellular Therapies Prices Public Offering of Common Stock -12.7%
3/6 Intra-Cellular Therapies Inc (NASDAQ: ITCI) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -13.4%
12/23 Intra-Cellular drug approval augurs well for CNS stocks, Stifel says [Seeking Alpha] -14.1%
7/8 Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression -16.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: